Report : North America Malaria Treatment Market Forecast to 2030 - Regional Analysis - by Treatment (Generic Drugs, Originators, Vaccines, and Others), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
At 29.1% CAGR, North America Malaria Treatment Market is Projected to be Worth US$ 487.31 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the North America malaria treatment market was valued at US$ 62.97 million in 2022 and is expected to reach US$ 487.31 million by 2030, registering a CAGR of 29.1% from 2022 to 2030. Extending pipeline of new drugs and vaccines and growing strategic initiatives are among the critical factors attributed to the North America malaria treatment market expansion.
Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.
A few antimalarial that are under clinical development are mentioned in the table below:
Table 1. Malaria Drugs/Vaccine/Compounds Under Clinical Development
Drug Developer Clinical Trial Stage
Artefenomel Sanofi Phase IIb
KAE609 Novartis AG Phase IIb
KAF156 Novartis AG Phase IIb
DSM265 Takeda Pharmaceutical Company Phase IIa
SANARIA PfSPZ-GA1 Sanaria Phase II
SANARIA PfSPZ Vaccine - Radiation Attenuated PfSPZ Vaccine Sanaria Phase II
SANARIA PfSPZ-CVac Sanaria Phase II
MSP3-CRM-Vac4All Vac4All Phase I
Liver-Stage Antigen-3 (LSA3) Vac4All Phase IIa
Source: Company Website, Business Market Insights Analysis
Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.
On the contrary, availability of counterfeit antimalarial drugs followed by subsequent drug resistance hurdles the growth of North America malaria treatment market.
Based on treatment, the North America malaria treatment market is categorized into generic drugs, originators, vaccines, and others. The vaccines segment held 92.2% share of North America malaria treatment market in 2022, amassing US$ 58.06 million. It is projected to garner US$ 452.23 million by 2030 to expand at 29.3% CAGR during 2022-2030.
In terms of route of administration, the North America malaria treatment market is bifurcated into oral and parenteral. The oral segment held 69.5% share of North America malaria treatment market in 2022, amassing US$ 43.74 million. It is projected to garner US$ 332.25 million by 2030 to expand at 28.8% CAGR during 2022-2030.
By distribution channel, the North America malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 43.3% share of North America malaria treatment market in 2022, amassing US$ 27.24 million. It is projected to garner US$ 211.72 million by 2030 to expand at 29.2% CAGR during 2022-2030.
Based on country, the North America malaria treatment market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.8% share of North America malaria treatment market in 2022. It was assessed at US$ 52.79 million in 2022 and is likely to hit US$ 404.74 million by 2030, exhibiting a CAGR of 29.0% during 2022-2030.
Key players operating in the North America malaria treatment market are Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, and Lupin Ltd, among others.
- In November 2022, Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria.
- In October 2021, GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com